In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 Stocks Turning Heads With Double-Digit Gains. Viridian Therapeutics ...

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the ...

Viridian Therapeutics (NASDAQ:VRDN) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

Viridian Therapeutics, Inc. VRDN shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 ...

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital reported selling its entire 3,200,000-share stake in Viridian Therapeutics. The net ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Viridian Therapeutics (NASDAQ:VRDN) in the last three months. The table below provides a concise ...

- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated ...